Thomas K. Equels, CEO and President of AIM ImmunoTech Inc. (NASDAQ: AIM), purchased 20,299 shares of company stock on November 6, 2026, at $0.156 per share for a total of $3,166. His beneficial ownership now stands at 210,046 shares.
The stock trades near its 52-week low of $0.15, down roughly 91% over the past year. AIM ImmunoTech's market capitalization stands at $4.63 million. InvestingPro analysis assigns a Fair Value of $0.20 to the stock.
Separately, Equels authored an article published in Breaking Defense exploring the potential of AIM ImmunoTech's drug Ampligen as a broad-spectrum antiviral therapeutic for diseases including Ebola and COVID-19. The company stated the article includes forward-looking statements about Ampligen's potential applications and future clinical trials. AIM ImmunoTech clarified that preclinical findings mentioned do not equate to FDA approval or confirm clinical efficacy in humans. The company furnished a copy of the article to the SEC as an exhibit.